| Literature DB >> 31260189 |
Jicheng Wang1,2, Shizhang Liu1, Jingyuan Li1, Zhi Yi1.
Abstract
Fibroblast growth factor (FGF) family members are important regulators of cell growth, proliferation, differentiation, and regeneration. The abnormal expression of certain FGF family members can cause skeletal diseases, including achondroplasia, craniosynostosis syndrome, osteoarthritis, and Kashin-Beck disease. Accumulating evidence shows that FGFs play a crucial role in the growth and proliferation of bone and in the pathogenesis of certain bone-related diseases. Here, we review the involvement of FGFs in bone-related processes and diseases; FGF1 in the differentiation of human bone marrow mesenchymal stem cells and fracture repair; FGF2, FGF9, and FGF18 in osteoarthritis; FGF6 in bone and muscle injury; FGF8 in osteoarthritis and Kashin-Beck disease; and FGF21 and FGF23 on bone regulation. These findings indicate that FGFs are targets for novel therapeutic interventions for bone-related diseases.Entities:
Keywords: abnormal expression; bone-related diseases; fibroblast growth factor; targeted therapy
Year: 2019 PMID: 31260189 DOI: 10.1111/cbdd.13588
Source DB: PubMed Journal: Chem Biol Drug Des ISSN: 1747-0277 Impact factor: 2.817